Two stocks in Biotechnology
Genmab A/S vs UCB: profit, growth, debt and price compared
UCB is stronger on 4 of 6 figures: profit margin, sales growth, debt and price for its expected profit. Genmab A/S is stronger on 2: analysts' view and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Genmab A/SGMAB.CO | UCBUCB.BR | |
|---|---|---|
| Net margin | 17.0% | Stronger: 25.7% |
| Revenue growth, past year | +16.10% | Stronger: +22.50% |
| Debt to equity | 82.1% | Stronger: 30.8% |
| Forward P/E | 29.9× | Stronger: 19.1× |
| Dividend yield | — | 0.51% |
| Analysts | Stronger: Strong buy · 13 | Buy · 19 |
| From its 200-day average | Stronger: +54.9% | +19.9% |
Share price over the past year
- Genmab A/S+74.3%
- UCB+20.8%
24 Nov 202518 Nov 2026
Genmab A/S or UCB: which is stronger?
- UCB.BR
Which is more profitable?
UCB keeps more of each sale as profit: 25.7% against 17.0%.
- UCB.BR
Which is growing its sales faster?
UCB is growing its sales faster: +22.50% over the past year, against +16.10%.
- UCB.BR
Which has borrowed less?
UCB has borrowed less: its debt is 30.8% of what its shareholders own, against 82.1% for Genmab A/S.
- UCB.BR
Which costs less for the profit it is expected to make?
UCB costs less for the profit it is expected to make: 19.1× its forward earnings, against 29.9×.
Which pays more in dividends?
UCB pays 0.51% a year in dividends for what a share costs, where Genmab A/S pays none.
- GMAB.CO
Which do analysts rate higher?
Analysts are warmer on Genmab A/S: Strong buy, against Buy for UCB.
- GMAB.CO
Which is in the stronger price trend?
Genmab A/S' price is in the stronger trend: 54.9% above its 200-day average, against 19.9% above.
What each company does
GMAB.COGenmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Reports results on 16 February 2027
UCB.BRUCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.